NCT00565968View on ClinicalTrials.gov

Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg

PHASE1CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

August 31, 2009

Conditions

Melanoma (Skin)

Interventions

DRUG

melphalan

DRUG

sorafenib tosylate

GENETIC

gene expression analysis

GENETIC

protein expression analysis

GENETIC

western blotting

OTHER

pharmacological study

Trial Locations (1)

10065

Memorial Sloan-Kettering Cancer Center, New York

Sponsors

Lead Sponsor

Duke University

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER